We are a clinical-stage biotechnology company developing novel therapeutics to meet the growing global need for effective, safe antiviral treatments. We employ a unique structure-based drug discovery technology platform and Nobel Prize-winning expertise to create viable antiviral drugs. Our antivirals target the replication process and are designed to be safe, broad-spectrum, resistant and convenient to administer.

We are quickly and efficiently advancing multiple antiviral candidates with clinical programs for norovirus, influenza and coronaviruses, while also discovering and developing antiviral compounds for other high-value indications.

Nasdaq Bell Ringing Ceremony

Overview

Cocrystal Pharma Presentation at ICAR 2026 Highlights Mechanism of Action and Clinical Advancement of CDI-988 for the Prevention and Treatment of Norovirus Infection

Apr 30, 2026

Read Press Release

2025

Year End Results

Dec 31, 2025

PDF HTML

Release

PDF HTML

10-K

HTML

Financials

ZIP XLS HTML

XBRL

Nasdaq:

COCP

Price

Change

Mkt Cap

Volume

52 week Low/High

Day Low/High

Sam Lee, Ph.D.

Co-Chief Executive Officer and President

Dr. Sam Lee has over 25 years of anti-infective drug discovery research experience. Prior to Cocrystal, he managed anti-infective drug discovery projects for eight years at Icos Corporation (Nasdaq: ICOS). At Icos, Dr. Lee was… View Full Bio

James J. Martin

Co-Chief Executive Officer and Chief Financial Officer

Mr. James Martin has over 25 years of finance and management experience including providing financial leadership to commercial-stage, publicly traded health science companies. Prior to Cocrystal, Mr. Martin served as the Chief Financial… View Full Bio

Roger Kornberg, Ph.D.

Chairman of the Board, Chief Scientist and Chairman of Scientific Advisory Board

Dr. Roger Kornberg is a member of the U.S. National Academy of Sciences and the Winzer Professor of Medicine in the Department of Structural Biology at Stanford University. He has been a member of the faculty of Stanford University since… View Full Bio

Steve Rubin

Vice Chairman

Mr. Steve Rubin is Executive Vice President-Administration and a director of OPKO Health, Inc. Previously, he was Senior Vice President and General Counsel of IVAX. Prior to IVAX, Mr. Rubin was Senior Vice President and General Counsel of… View Full Bio

Phillip Frost, M.D.

Director

Dr. Phillip Frost is the Chairman and CEO of OPKO Health, Inc. (NYSE: OPK). Dr. Frost is the former Chairman of the Board of Teva Pharmaceuticals (NYSE: TEVA). Dr. Frost served as Chairman and CEO of IVAX Corporation from 1987 through that… View Full Bio

Fred Hassan

Director

Mr. Hassan is Chairman of the investment firm Caret Group and a Director of Warburg Pincus LLC, a global private equity firm. From 2003 to 2009 Mr. Hassan served as Chairman and Chief Executive Officer of Schering-Plough and from 2001 to… View Full Bio

Richard C. Pfenniger, Jr.

Director

Mr. Pfenniger is a private investor who served as Interim CEO of Vein Clinics of America, Inc., a privately held company that specializes in the treatment of vein disease, from May 2014 to February 2015, and as Interim CEO of IntegraMed… View Full Bio

Overview

Latest News

Latest Financial Results

2025

Stock Information

Nasdaq:

Price

Change

Mkt Cap

Volume

Officers & Directors

Sam Lee, Ph.D.

James J. Martin

Roger Kornberg, Ph.D.

Steve Rubin

Phillip Frost, M.D.

Fred Hassan

Richard C. Pfenniger, Jr.

Overview

Latest News

Sign up for email alerts

Latest Financial Results

2025

Stock Information

Nasdaq:

Price

Change

Mkt Cap

Volume

Officers & Directors

Sam Lee, Ph.D.

James J. Martin

Roger Kornberg, Ph.D.

Steve Rubin

Phillip Frost, M.D.

Fred Hassan

Richard C. Pfenniger, Jr.